Evie Robson

Dr. Evie Robson


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
EREvie Robson
Evie Robson
LDLuke Dixon
Luke Dixon
LCLiam Causon
Liam Causon
WDWilliam Dawes
William Dawes
MBMassimo Benenati
Massimo Benenati
COChristopher O'Callaghan
Christopher O'Callaghan
Objective To report a neuroradiologic phenotype associated with reduced generation of multiple motile cilia (RGMC) and mutations in the multicilin gene. We hypothesize that the observed phenotype may reflect the emerging role that ependymal cilia play in regulating CSF production. Method Clinical and radiologic records were retrospectively reviewed for 7 consecutive patients diagnosed by the Leicester UK national primary ciliary dyskinesia (PCD) diagnostic laboratory. Results On MRI scanning, all patients demonstrated hydrocephalus, choroid plexus hyperplasia (CPH), and arachnoid cysts. No patient had any sign of neurologic deficit. All patients had significant lung disease. Conclusions We conclude that there is a high incidence of hydrocephalus, arachnoid cysts, and CPH in MCIDAS-associated RGMC. In all cases, the observed hydrocephalus seems arrested in childhood without progression or adverse neurologic sequelae. Our new observation of CPH, which is associated with CSF overproduction, is the first macroscopic evidence that ependymal cilia may be involved in the regulation of CSF production and flow. We suggest that brain imaging should be performed in all cases of RGMC and that a diagnosis of PCD or RGMC be strongly considered in patients with unexplained hydrocephalus and a lifelong “wet”-sounding cough.

16 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CDCorine Driessens
Corine Driessens
SCSiobhan Carr
Siobhan Carr
ECEdel Clough
Edel Clough
FCFiona Copeland
Fiona Copeland
SDSharon Dell
Sharon Dell
LBLaura Behan
Laura Behan
Primary ciliary dyskinesia (PCD) is an incurable, rare, inherited, chronic condition. Treatment includes the regular clearing of airway mucus, aggressive treatment of infections and management of hearing loss. Caregiver burden has not been explored, hence we interviewed 18 mothers and 6 fathers of children under 6 years to understand the impact of diagnostic testing and implications of a positive diagnosis. Interviews were transcribed and thematically analysed and five key themes were identified. These included the parents’ experiences following child’s diagnosis, impact of child’s treatment regimen on parent, impact of child’s health status on parent, parent’s coping strategies, and parental concerns for the future. Parents described their diagnostic journey, with the findings revealing how a lack of awareness among clinicians of the PCD symptom pattern can lead to a delayed diagnosis. Parents discussed the emotional and practical impact of a PCD diagnosis and the coping strategies employed to deal with challenges arising following a diagnosis. Parents use a variety of different lifestyle changes to accommodate their child’s treatment regimen and to cope with disruptive life events such as the COVID-19 pandemic. This study provides valuable insights into parental adjustment and adaptation to a PCD diagnosis and management regimen. Going forward, this research highlights the need for integrated social care for PCD patients and their families.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
EREvie Robson
Evie Robson
SBSurinder Birring
Surinder Birring
RFRichard Feltbower
Richard Feltbower
COChristopher O'CAllaghan
Christopher O'CAllaghan
DPDaniel Peckham
Daniel Peckham
Background: Primary Ciliary Dyskinesia (PCD) is a rare disease leading to recurrent respiratory tract infections and bronchiectasis. Robust objective measures of disease surveillance are required. Methods: Night-time cough frequency (coughs per hour (c/hr)) was reported in adults and children attending Leeds teaching hospitals. Individuals with PCD (n=23) were compared with pre-modulator CF (CF, n=27)) and healthy controls (HC, n=21) at baseline health and during and after significant respiratory exacerbations requiring intravenous antibiotics. Results: Adults with CF had a higher baseline cough frequency (3.4c/hr) when compared to adults with PCD (0.69c/hr) and HC (0.28c/hr). Children with PCD had higher baseline cough frequency (0.82c/hr) than children with CF (0.14c/hr) and HC (0.16c/hr). A decrease in cough frequency between the start of exacerbation and 4 weeks post treatment were observed in both the PCD and CF groups (4.3c/hr to 1.05c/hr for PCD and 3.98c/hr to 1.43c/hr for CF). Table: Median baseline cough frequency, measured as c/hr Conclusion: These findings highlight differences in night-time cough frequency between PCD and CF. Night-time cough frequency surveillance has the potential of being a practical and objective marker of response to treatment and an early detection tool which could enable prompt intervention.

2 November 2026 in Pediatric Pulmonology
Verified
Journal Article
Open access
PDF file
HSHollie Smith
Hollie Smith
SCSiobhan Carr
Siobhan Carr
SUStefan Unger
Stefan Unger
KUKirstin Unger
Kirstin Unger
WKWanda J Kozlowska
Wanda J Kozlowska
PKPriti Kenia
Priti Kenia
Background: Paediatric bronchiectasis (PB) unrelated to cystic fibrosis or primary ciliary dyskinesia causes significant morbidity and impairs quality of life (QoL) for children and their families. An international consensus ranked a paediatric‐specific QoL measure as the highest research priority, yet no self‐report instrument exists for children and young people. We aimed to establish professional consensus on candidate items and domains to inform the development of age specific PB QoL questionnaires. Methods: Candidate items were drawn verbatim from two validated paediatric respiratory instruments (QOL‐PCD and CFQ‐R), guided by published evidence. Multidisciplinary professionals from the Paediatric Bronchiectasis Network, United Kingdom (PBNetUK) rated items for child (6–12 years), young person (13–17 years) and parent proxy (6–12 years) over 2 e‐Delphi rounds (≥ 70% agreement). A core group, including a parent representative finalised item sets. Feasibility was checked with 30 patients and parents. Results: Of 34 professionals invited, 26, 21 and 20 rated the child (28 items), young person (36 items) and parent‐proxy (33 items) versions in round one; round two retention was 90%–96%. Final versions comprised 19, 27 and 20 items across eight domains, with a 4‐week recall period. For feasibility, participants rated length as appropriate (28/30) and items as easy to understand (mean 8.0–9.4/10). Conclusions: This professional consensus provides a candidate item pool and proposed domain framework that will guide the next stages of QoL questionnaire development ‐ establishing content validity through concept elicitation and cognitive interviews with children, young people and parents, followed by psychometric validation to produce a validated QoL.